YOLFTbeta
Alpha Tau Medical Ltd

Alpha Tau Medical Ltd

DRTS · NASDAQ · Healthcare / Biotechnology

13.38USD+0.02 (+0.15%)

Price History

Full chart

Market Stats

Previous Close13.36
Open13.45
Day Range12.98 – 13.49
52-Week Range3.43 – 15.79
Volume403.52K
Market Cap1.37B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.06
Dividend Yield0.00%
Beta1.21
50-Day Avg13.91
200-Day Avg9.50

About

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Uzi Sofer
  • Employees121
  • HeadquartersKiryat HaMada St. 5, Jerusalem, Israel, 9777605, USA
  • Websitehttps://www.alphatau.com

Leadership

  • Mr. Uzi SoferCEO & Chairman · b. 1970
  • Mr. Raphi LevyChief Financial Officer · b. 1985
  • Mr. Amnon GatChief Operations Officer · b. 1975
  • Mr. Ronen SegalChief Technology Officer · b. 1973
  • Ms. Rebecca BeckerVice President of legal
  • Ms. Yael ZeigerCorporate Controller · b. 1983

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue-86.00K776.00K979.00K1.07M1.10M1.23M
Gross Profit--86.00K-776.00K-979.00K-1.07M-1.10M-1.23M
Operating Expense-9.16M13.01M31.16M34.61M34.94M41.06M
Operating Income-8.01M-9.24M-13.79M-32.14M-35.68M-36.04M-42.29M
EBITDA-7.94M-9.16M-13.01M-31.16M-27.99M-30.34M-41.06M
Net Income-8.46M-8.88M-27.27M-33.76M-29.16M-31.75M-42.63M
R&D6.64M7.46M11.45M20.89M26.42M27.02M30.83M
Interest Expense1.28M217.00K12.70M1.77M75.00K303.00K419.00K

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets31.56M52.99M42.22M120.15M107.39M86.20M106.58M
Total Liabilities31.75M61.42M76.99M14.49M22.91M23.54M29.48M
Total Equity-193.00K-8.43M-34.78M105.66M84.47M62.67M77.10M
Cash1.83M15.60M23.24M5.84M12.66M13.72M15.98M
Total Debt-53.96M53.96M5.19M13.28M12.54M13.73M
Net Debt-1.83M38.37M30.73M-643.00K619.00K-1.19M-2.25M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.91M-7.25M-11.81M-23.88M-17.96M-19.78M-26.68M
Investing Cash Flow-10.16M-7.82M19.27M-89.94M18.68M20.77M-20.59M
Financing Cash Flow5.32M29.32M111.00K96.91M5.30M25.00K45.77M
Capital Expenditure1.29M3.77M2.93M904.00K6.40M2.24M6.08M
Free Cash Flow-8.20M-11.02M-14.74M-24.78M-24.36M-22.02M-32.76M
FCF to OCF118.71%151.95%124.78%103.79%135.64%111.31%122.77%

Earnings

Report DateJan 13, 2021May 28, 2021Aug 16, 2021Nov 15, 2021Mar 28, 2022May 26, 2022Aug 25, 2022Nov 22, 2022Mar 9, 2023May 23, 2023Aug 28, 2023Nov 16, 2023Mar 7, 2024May 20, 2024Aug 14, 2024Nov 19, 2024Mar 12, 2025May 19, 2025Aug 11, 2025Nov 20, 2025Mar 5, 2026May 18, 2026Aug 10, 2026Nov 19, 2026
EPS Estimate0.00---0.06-0.26-0.08-0.12-0.12-0.11-0.11-0.13-0.12-0.12-0.13-0.12-0.12-0.13-0.14-0.11-0.12-0.12-0.12-0.14-0.14
EPS Actual0.000.23-0.070.01-0.29-0.54-0.03-0.04-0.05-0.12-0.12-0.25-0.11-0.11-0.11-0.10-0.13-0.12-0.13-0.14-0.14-0.26-0.50-
Surprise---116.67%-11.54%-575.00%75.00%66.67%54.55%-9.09%7.69%-108.33%8.33%15.38%8.33%16.67%0.00%14.29%-18.18%-16.67%-13.54%-116.67%-257.14%-
Timing-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.37B
Enterprise Value1.31B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book31.79
EPS-1.06
Book Value0.477
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-48.76M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-141.68%
Return on Assets-25.71%
Shares Outstanding92.48M
Shares Float64.10M
Beta1.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 17.80
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
9.15%
Insiders
30.50%
Retail / Other
60.35%

Top Institutional Holders

  • Gem Investment Advisors, LLC
    1.43M1.55%
  • HighTower Advisors, LLC
    874.99K0.95%
  • Aquamarine Financial (Cayman) Ltd
    721.50K0.78%
  • Pier Capital, LLC
    691.94K0.75%
  • Apella Capital, LLC
    382.28K0.41%
  • ARK Investment Management LLC
    292.13K0.32%
  • UBS Group AG
    286.69K0.31%
  • Mariner Wealth Advisors LLC
    146.40K0.16%
  • Daytona Street Capital LLC
    146.11K0.16%
  • Kovitz Investment Group Partners, LLC
    135.02K0.15%
  • Easterly Investment Partners.
    128.59K0.14%
  • Jane Street Group LLC
    75.54K0.08%

Top Fund Holders

  • iShares Core MSCI EAFE ETF
    464.45K0.50%
  • SEB Nordamerikafond Småbolag
    275.00K0.30%
  • iShares MSCI EAFE Small-Cap ETF
    204.25K0.22%
  • ARK Israel Innovative Technology ETF
    184.38K0.20%
  • Adara Smaller Companies
    134.70K0.15%
  • iShares MSCI Israel ETF
    134.22K0.15%
  • Dunham Small Cap Growth N
    71.66K0.08%
  • iShares Core MSCI Total Intl Stk ETF
    62.98K0.07%